openPR Logo
Press release

Investors who lost money with shares of Proto Labs, Inc. (NYSE: PRLB) should contact the Shareholders Foundation in connection with Investigation

An investigation for investors in Proto Labs, Inc. (NYSE: PRLB) shares over potential securities laws violations by Proto Labs.

An investigation for investors in Proto Labs, Inc. (NYSE: PRLB) shares over potential securities laws violations by Proto Labs.

An investigation was announced on behalf of investors of Proto Labs, Inc. (NYSE: PRLB) shares over potential securities laws violations by Proto Labs, Inc. in connection with certain financial statements.

Investors who purchased shares of Proto Labs, Inc. (NYSE: PRLB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Proto Labs, Inc. (NYSE: PRLB) concerning whether a series of statements by Proto Labs, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Maple Plain, MN based Proto Labs, Inc., together with its subsidiaries, operates as a digital manufacturer of custom parts in the United States and Europe. Proto Labs, Inc. reported that its annual Total Revenue rose from $488.39 million in 2022 to $503.87 million in 2023, and that its Net Loss of $103.46 million turned to a Net Income of $17.22 million in 2023.

On November 4, 2022, Proto Labs, Inc reported Q3 results meeting the low end of its prior guidance and then announced lower than expected guidance for Q4 2024. Proto attributed it to "a decline in our injection molding revenue, predominantly due to the challenging macroeconomic climate" in addition to the negative impacts of foreign currency and "the closure of [Proto's] Japan operation." Analysts were skeptical of Proto's explanation, pointing to increased competition as an alternate contributing factor for the decline.

Shares of Proto Labs, Inc. (NYSE: PRLB) declined from $53.00 per share on August 05, 2022, to as low as $22.04 per share on November 09, 2022.

Those who purchased shares of Proto Labs, Inc. (NYSE: PRLB) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About:
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investors who lost money with shares of Proto Labs, Inc. (NYSE: PRLB) should contact the Shareholders Foundation in connection with Investigation here

News-ID: 3660151 • Views:

More Releases from Shareholders Foundation, Inc.

Investors who lost money with shares of Elevance Health, Inc. (NYSE: ELV) should contact the Shareholders Foundation in connection with Lawsuit
Investors who lost money with shares of Elevance Health, Inc. (NYSE: ELV) should …
An investor in shares of Elevance Health, Inc. (NYSE: ELV) filed a lawsuit over alleged violations of Federal Securities Laws by Elevance Health, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Elevance Health, Inc. (NYSE: ELV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 11, 2025. NYSE: ELV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Lawsuit filed for Investors who lost money with Bitfarms Ltd. (NASDAQ: BITF) shares
Lawsuit filed for Investors who lost money with Bitfarms Ltd. (NASDAQ: BITF) sha …
An investor, who purchased shares of Bitfarms Ltd. (NASDAQ: BITF), filed a lawsuit over alleged violations of Federal Securities Laws by Bitfarms Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Bitfarms Ltd. (NASDAQ: BITF) have certain options and for certain investors are short and strict deadlines running. Deadline: July 8, 2025. NASDAQ: BITF investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Lawsuit filed for Investors who lost money with shares of Compass Diversified (NYSE: CODI)
Lawsuit filed for Investors who lost money with shares of Compass Diversified (N …
An investor, who purchased shares of Compass Diversified (NYSE: CODI), filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by Compass Diversified. Investors who purchased shares of Compass Diversified (NYSE: CODI) have certain options and for certain investors are short and strict deadlines running. Deadline: July 8, 2025. NYSE: CODI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Investigation announced for Long-Term Investors in shares of AppLovin Corporation (NASDAQ: APP) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of AppLovin Corporatio …
An investigation was announced for potential breaches of fiduciary duties by certain directors of AppLovin Corporation. Investors who are current long term investors in AppLovin Corporation (NASDAQ: APP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: APP stocks follows a lawsuit filed against AppLovin Corporation over alleged securities

All 5 Releases


More Releases for Proto

Global Torque Wrench Market 2018 - Snap-on, Norbar, Proto, TONE, Tohnichi
Apex Market Reports, recently published a detailed market research study focused on the “Torque Wrench Market” across the global, regional and country level. The report provides 360° analysis of “Torque Wrench Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Torque Wrench Market
Global Proto-Oncogene Market and Clinical Pipeline Insight 2024 Report
“Global Proto Oncogene Market and Clinical Pipeline Insight 2024” report highlights: * Oncogenes as Therapeutic Targets for Treatment * Market Analysis of Proto Oncogene Therapeutic Drugs * Dosage and Price Analysis of Drugs * Patent and Approval Year Insight * Proto Oncogene Inhibitors Clinical Pipeline by Company, Indication and Phase * Marketed Proto Oncogene Inhibitors Clinical Insight by Company and Indication Download Report Sample Weblink: https://www.kuickresearch.com/report-global-proto-oncogene-market-and-clinical-pipeline-insight-2024.php For Report Sample Contact: neeraj@kuickresearch.com Table of Contents 1. Introduction
RAF Proto Oncogene SerineThreonine Protein Kinase (Proto Oncogene c RAF or RAF1 …
ReportsWorldwide has announced the addition of a new report title RAF Proto Oncogene SerineThreonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2017'; RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
Torque Wrench Market 2017 - TONE, Proto, Snap-on, Norbar, Tohnichi
Apex Market Researchs, recently published a detailed market research study focused on the "Torque Wrench Market" across the global, regional and country level. The report provides 360° analysis of "Torque Wrench Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Torque Wrench industry, and estimates the future trend of Torque Wrench market
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “RAF Proto Oncogene Serine/Threonine Protein Kinase - Pipeline Review, H2 2017”, targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 6, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages
GLOBAL TORQUE WRENCH MARKET 2017- PROTO, TOHNICHI, TONE, ENERPAC
The Industry Study on Global Torque Wrench Market 2017 incorporates the entire aspects of the Torque Wrench market. This includes extensive analysis, recent industry statistics and upcoming flow of the Torque Wrench market. The report also describes the size of the Torque Wrench market, factors controlling Torque Wrench market growth, various challenges which affect market expansion and economic prominence of the Torque Wrench market globally. Global Torque Wrench Market report commences